APA (7th ed.) Citation

Megna, M., Potestio, L., Ruggiero, A., Camela, E., & Fabbrocini, G. (2022). Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study. Dermatologic Therapy, 35(7), 1. https://doi.org/10.1111/dth.15524

Chicago Style (17th ed.) Citation

Megna, Matteo, Luca Potestio, Angelo Ruggiero, Elisa Camela, and Gabriella Fabbrocini. "Risankizumab Treatment in Psoriasis Patients Who Failed Anti‐IL17: A 52‐week Real‐life Study." Dermatologic Therapy 35, no. 7 (2022): 1. https://doi.org/10.1111/dth.15524.

MLA (9th ed.) Citation

Megna, Matteo, et al. "Risankizumab Treatment in Psoriasis Patients Who Failed Anti‐IL17: A 52‐week Real‐life Study." Dermatologic Therapy, vol. 35, no. 7, 2022, p. 1, https://doi.org/10.1111/dth.15524.